Polypharmacy with antidepressants in children and adolescents.
暂无分享,去创建一个
Celso Arango | Carmen Moreno | C. Arango | M. Parellada | C. Díaz-Caneja | Mara Parellada | Covadonga M Díaz-Caneja | Ana Espliego | A. Espliego | C. Moreno | C. Diaz-Caneja
[1] J. Alda,et al. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. , 2010, Bipolar disorders.
[2] H. Pincus,et al. Concomitant pharmacotherapy among youths treated in routine psychiatric practice. , 2005, Journal of child and adolescent psychopharmacology.
[3] R. Findling. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. , 1996, Journal of child and adolescent psychopharmacology.
[4] S. Mitchell,et al. Seizures induced by the combination treatment of methylphenidate and sertraline. , 2008 .
[5] G. Perugi,et al. Pharmacotherapy in Paediatric Obsessive-Compulsive Disorder , 2009, CNS drugs.
[6] F. Lynch,et al. Rising prevalence of antidepressants among US youths. , 2002, Pediatrics.
[7] G. Carlson,et al. Increased Rates of Bipolar Disorder Diagnoses Among U.S. Child, Adolescent, and Adult Inpatients, 1996–2004 , 2007, Biological Psychiatry.
[8] Robert D Gibbons,et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. , 2006, The American journal of psychiatry.
[9] K. Merikangas,et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A). , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.
[10] E. Hunkeler,et al. Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994-2003. , 2005, Journal of child and adolescent psychopharmacology.
[11] Andrés Martin,et al. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. , 2003, Psychiatric services.
[12] C. Correll,et al. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.
[13] L. Greenhill,et al. Pharmacotherapy of child and adolescent depression. , 2006, Child and adolescent psychiatric clinics of North America.
[14] H. Tobi,et al. Psychotropic co-medication among stimulant-treated children in The Netherlands. , 2005, Journal of child and adolescent psychopharmacology.
[15] S. Cahill,et al. Post-traumatic stress disorder and acute stress disorder I: their nature and assessment considerations. , 2005, Psychiatry (Edgmont (Pa. : Township)).
[16] C. Arango,et al. Características diferenciales de eficacia y tolerabilidad de los antipsicóticos de segunda generación en el tratamiento de trastornos psicóticos en niños y adolescentes , 2010 .
[17] R. Johann-Liang,et al. Off‐label prescribing patterns of antidepressants in children and adolescents , 2012, Pharmacoepidemiology and drug safety.
[18] D. Clemow,et al. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. , 2005, The Journal of clinical psychiatry.
[19] A. Awasthi,et al. Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin. , 2005, Journal of child and adolescent psychopharmacology.
[20] Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study , 2012 .
[21] A. Nardi,et al. Body dysmorphic disorder treated with bupropion: cases report. , 2005, The Australian and New Zealand journal of psychiatry.
[22] R. Aparasu,et al. Extent of functional impairment in children and adolescents with depression , 2010, Current medical research and opinion.
[23] R. Kowatch,et al. Successful treatment of trichotillomania with olanzapine augmentation in an adolescent. , 2004, Journal of child and adolescent psychopharmacology.
[24] H. Tobi,et al. Antidepressant prevalence for youths: a multi‐national comparison , 2006, Pharmacoepidemiology and drug safety.
[25] M. Weissman,et al. National trends in the use of psychotropic medications by children. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.
[26] C. Nemeroff,et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. , 2007, Archives of general psychiatry.
[27] M. A. Adeoye,et al. Psychotropic Drug-Related Eosinophilia With Systemic Symptoms After Acute Caffeine Ingestion , 2011, Pediatrics.
[28] R. Ferrell,et al. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. , 2000, Journal of child and adolescent psychopharmacology.
[29] M. Strober,et al. The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.
[30] M. Trivedi,et al. Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.
[31] C. Essau. Comorbidity of depressive disorders among adolescents in community and clinical settings , 2008, Psychiatry Research.
[32] Michael J Wade,et al. Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York. , 2005, Journal of child and adolescent psychopharmacology.
[33] A. Josephson,et al. Combined methylphenidate and imipramine complication. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.
[34] Harold Alan Pincus,et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. , 2007, JAMA.
[35] J. Biederman,et al. Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.
[36] J. Biederman,et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.
[37] Alan Apter,et al. Psychiatric aspects of pediatric cancer. , 2003, Child and adolescent psychiatric clinics of North America.
[38] R. Valuck,et al. Persisting decline in depression treatment after FDA warnings. , 2009, Archives of general psychiatry.
[39] P. Bentivoglio,et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.
[40] M. Rynn,et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. , 2003, JAMA.
[41] References , 1971 .
[42] A. Mack,et al. Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials , 2009 .
[43] E. Storch,et al. Clinical features associated with treatment-resistant pediatric obsessive-compulsive disorder. , 2008, Comprehensive psychiatry.
[44] J. Micallef,et al. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002 , 2006, Pharmacoepidemiology and drug safety.
[45] M. Lopez-Larson,et al. Empirical Evidence for the Use of Lithium and Anticonvulsants in Children with Psychiatric Disorders , 2006, Harvard review of psychiatry.
[46] K. J. Took,et al. Enuresis with combined risperidone and SSRI use. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.
[47] J. Bridge,et al. Psychotropic Medication Changes, Polypharmacy, and the Risk of Early Readmission in Suicidal Adolescent Inpatients , 2009, The Annals of pharmacotherapy.
[48] Golda S. Ginsburg,et al. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.
[49] Carmen Moreno,et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons , 2011, European Neuropsychopharmacology.
[50] John S. March,et al. Practice Parameters for the Assessment and Treatment of Children and Adolescents With Obsessive-Compulsive Disorder , 1998 .
[51] A. Dean,et al. Psychotropic medication utilization in a child and adolescent mental health service. , 2006, Journal of child and adolescent psychopharmacology.
[52] B. Birmaher,et al. Treatment guidelines for children and adolescents with bipolar disorder. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.
[53] M. Coskun,et al. Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. , 2008, Journal of clinical psychopharmacology.
[54] M. Olfson,et al. National trends in the treatment of attention deficit hyperactivity disorder. , 2003, The American journal of psychiatry.
[55] N. Alessi,et al. Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder. , 1991, The American journal of psychiatry.
[56] R. Muñoz,et al. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2000 , 2002 .
[57] Wilbur L. Smith,et al. Case study: obsessive-compulsive disorder after severe traumatic brain injury in an adolescent. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.
[58] W. Klykylo,et al. Medication-induced seizures. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.
[59] O. Oner,et al. Psychopharmacology of pediatric obsessive-compulsive disorder: three case reports , 2008, Journal of psychopharmacology.
[60] H. Akiskal,et al. Bipolar co-morbidity in pediatric obsessive-compulsive disorder: clinical and treatment implications. , 2007, Journal of child and adolescent psychopharmacology.
[61] T. Hyde,et al. Neuroleptic-induced tardive dyskinesia. , 1996, The American journal of psychiatry.
[62] R. McIntyre,et al. Cardiovascular and Neurological Adverse Events Associated With Antidepressant Treatment in Children and Adolescents , 2009, Journal of child neurology.
[63] N. Ghaziuddin,et al. Myoclonus during prolonged treatment with sertraline in an adolescent patient. , 2001, Journal of child and adolescent psychopharmacology.
[64] R. Raghavan,et al. Use of multiple psychotropic medications among adolescents aging out of foster care. , 2008, Psychiatric services.
[65] N. Crossley,et al. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. , 2007, The Journal of clinical psychiatry.
[66] D. Elkind. Children and adolescents , 1970 .
[67] J. Stockman. Lifetime Prevalence of Mental Disorders in U.S. Adolescents: Results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A) , 2012 .
[68] H. Duggal,et al. Treating selective serotonin reuptake inhibitor-induced behavioral activation with valproate. , 2003, Journal of child and adolescent psychopharmacology.
[69] J. McKenzie,et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. , 2007, The Cochrane database of systematic reviews.
[70] W. A. Newman Dorland,et al. Dorland's Illustrated Medical Dictionary , 1974 .
[71] C. Debattista,et al. Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression , 2009, CNS drugs.
[72] M. Davies,et al. Psychosocial functioning in prepubertal major depressive disorders. I. Interpersonal relationships during the depressive episode. , 1985, Archives of general psychiatry.
[73] Rebecca Tillman,et al. Pharmacological and non-drug treatment of child bipolar I disorder during prospective eight-year follow-up. , 2010, Bipolar disorders.
[74] D. Connor,et al. Combined pharmacotherapy in children and adolescents in a residential treatment center. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.
[75] D. Rosenberg,et al. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. , 1999, Journal of child and adolescent psychopharmacology.
[76] O. Moghraby,et al. Depression in children and young people: identification and management in primary, community and secondary care (NICE guideline CG28) , 2015, Archives of Disease in Childhood: Education & Practice Edition.
[77] B. Vitiello. An international perspective on pediatric psychopharmacology , 2008, International review of psychiatry.
[78] Golda S. Ginsburg,et al. Clinical characteristics of anxiety disordered youth. , 2010, Journal of anxiety disorders.
[79] M. Bracken,et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder , 2006, Molecular Psychiatry.
[80] Andrés Martin,et al. Pediatric Psychopharmacology: Principles and Practice , 2002 .
[81] J. Lijmer,et al. Pharmacological treatment of psychotic depression Wijkstra , 2018 .
[82] N. Halfon,et al. Patterns of Comorbidity, Functioning, and Service Use for US Children With ADHD, 2007 , 2011, Pediatrics.
[83] M. Nigro,et al. Topiramate effectiveness in Prader-Willi syndrome. , 2003, Pediatric neurology.
[84] S. Faraone,et al. Effect of stimulants on height and weight: a review of the literature. , 2008, Journal of the American Academy of Child and Adolescent Psychiatry.
[85] G. Gammon,et al. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. , 1993, Journal of child and adolescent psychopharmacology.
[86] E. Settle. Antidepressant drugs: disturbing and potentially dangerous adverse effects. , 1998, The Journal of clinical psychiatry.
[87] K. Ružić,et al. Olanzapine treatment in anorexia nervosa: case report. , 2009, Psychiatria Danubina.
[88] Erin S. Johns,et al. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. , 2005, Journal of child and adolescent psychopharmacology.
[89] M. Olfson,et al. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. , 2007, Archives of general psychiatry.
[90] A. Sourander. Combined psychopharmacological treatment among child and adolescent inpatients in Finland , 2004, European child & adolescent psychiatry.
[91] L. Namerow,et al. Citalopram for OCD and Tourette's syndrome. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.
[92] N. Ryan,et al. Lithium antidepressant augmentation in TCA-refractory depression in adolescents. , 1988, Journal of the American Academy of Child and Adolescent Psychiatry.
[93] G. Glaeske,et al. A three-country comparison of psychotropic medication prevalence in youth , 2008, Child and adolescent psychiatry and mental health.
[94] D. Safer,et al. Concomitant psychotropic medication for youths. , 2003, The American journal of psychiatry.
[95] Z. Zadik,et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. , 2002, Archives of pediatrics & adolescent medicine.
[96] F. Snoek,et al. Depressive symptoms and unmet psychological needs of Dutch youth with type 1 diabetes: results of a web‐survey , 2011, Pediatric diabetes.
[97] R. Bruun,et al. Combined pharmacotherapy risk. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.
[98] D. Safer,et al. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. , 2006, Journal of child and adolescent psychopharmacology.
[99] C. Arango,et al. Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents , 2010 .
[100] D. Stein,et al. Combined pharmacotherapy for TS and OCD. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.
[101] Y. Levkovitch,et al. Can clozapine trigger OCD? , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.
[102] M. Olfson,et al. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.
[103] R. Srivastava,et al. Olanzapine augmentation of fluoxetine in trichotillomania: two cases. , 2005, The Australian and New Zealand journal of psychiatry.
[104] M. Olfson,et al. Relationship between antidepressant medication treatment and suicide in adolescents. , 2003, Archives of general psychiatry.
[105] David Brent,et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.
[106] B. Vitiello,et al. National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge , 2004, Journal of attention disorders.
[107] J. Walkup. Practice parameter on the use of psychotropic medication in children and adolescents. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.
[108] E. Vieta,et al. Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials , 2010, Journal of clinical psychopharmacology.
[109] M. Zonfrillo,et al. Pediatric psychotropic polypharmacy. , 2005, Psychiatry (Edgmont (Pa. : Township)).
[110] C. Varley,et al. Pediatric Psychopharmacology: Principles and Practice , 2003 .
[111] R. McIntyre,et al. Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. , 2009, The Journal of clinical psychiatry.
[112] J. Racoosin,et al. Suicide Rates in Short-term Randomized Controlled Trials of Newer Antidepressants , 2006, Journal of clinical psychopharmacology.
[113] A. Varan,et al. Olanzapine treatment of an adolescent girl with anorexia nervosa , 2003, Human psychopharmacology.
[114] M. Bonati,et al. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: A systematic review and meta-analysis , 2008, European Neuropsychopharmacology.
[115] James McCracken,et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.
[116] R. Findling,et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. , 2004, The American journal of psychiatry.
[117] Dan J Stein,et al. Selective serotonin reuptake inhibitors in children and adolescents. , 2002, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[118] R. Stafford,et al. Depression treatment during outpatient visits by U.S. children and adolescents. , 2005, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[119] Ö. Özcan,et al. Self-injury behavior in an adolescent with Wilson’s disease , 2009, European Child and Adolescent Psychiatry.
[120] J. Crayton,et al. Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report. , 2001, Journal of clinical psychopharmacology.
[121] F. Keller,et al. Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. , 2009, Journal of child and adolescent psychopharmacology.
[122] D. Sclar,et al. Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. , 2009, Clinical therapeutics.
[123] G. Walter,et al. Lithium Augmentation of Venlafaxine in Adolescent Major Depression , 1998, The Australian and New Zealand journal of psychiatry.
[124] B. Leventhal,et al. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder. , 2002, Journal of child and adolescent psychopharmacology.
[125] J. Newcorn,et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.
[126] J. Biederman,et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. , 2003, Journal of child and adolescent psychopharmacology.
[127] Jonathan C. Craig,et al. Clinical trials in children. , 2015, British journal of clinical pharmacology.
[128] P. Owens,et al. Multiple psychotropic medication use for youths: a two-state comparison. , 2005, Journal of child and adolescent psychopharmacology.
[129] G. Emslie,et al. Review of the efficacy and safety of antidepressants in youth depression. , 2005, Journal of child psychology and psychiatry, and allied disciplines.
[130] J. Stockman,et al. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. , 2004, JAMA.
[131] C. Pfanner,et al. Aripiprazole Augmentation in 39 Adolescents With Medication-Resistant Obsessive-Compulsive Disorder , 2010, Journal of clinical psychopharmacology.
[132] R. Bussing,et al. Methamphetamine and fluoxetine treatment of a child with attention-deficit hyperactivity disorder and obsessive-compulsive disorder. , 1993, Journal of child and adolescent psychopharmacology.
[133] D. Wiggins,et al. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. , 1990, Psychopharmacology bulletin.
[134] Daniela Berardi. Statement of interest , 2002, Description Logics.
[135] H. Tobi,et al. Psychotropic medication in children: a study from the Netherlands. , 2001, Pediatrics.
[136] L. Soorya,et al. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. , 2006, Journal of clinical psychopharmacology.
[137] C. Bell. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision: DSM-IV-TR Quick Reference to the Diagnostic Criteria from DSM-IV-TR , 2001 .
[138] A. Vance,et al. Single and Combined Psychotropic Medication Use in a Child and Adolescent Mental Health Service , 2004, The Australian and New Zealand journal of psychiatry.
[139] S. Faraone,et al. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. , 2000, Journal of child and adolescent psychopharmacology.
[140] M. Kölch,et al. Antidepressant use in children and adolescents in Germany. , 2006, Journal of child and adolescent psychopharmacology.
[141] C. Good. Adjunctive quetiapine targets self-harm behaviors in adolescent females with major depressive disorder. , 2006, Journal of child and adolescent psychopharmacology.
[142] C. Roberts,et al. Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. , 2006, The British journal of psychiatry : the journal of mental science.
[143] P. Thomsen. Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series. , 2004, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[144] Sarah A. Mustillo,et al. Prevalence and development of psychiatric disorders in childhood and adolescence. , 2003, Archives of general psychiatry.
[145] M. Chassin,et al. Can experts agree when to hospitalize adolescents? , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.
[146] D. Coghill,et al. Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder , 2008, CNS drugs.
[147] H. Mikkelsen,et al. The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases , 1999, European Child & Adolescent Psychiatry.
[148] P. Russell,et al. Predictive factors for polypharmacy among child and adolescent psychiatry inpatients , 2006, Clinical practice and epidemiology in mental health : CP & EMH.
[149] P. Kendall,et al. Prevalence and co-morbidity among anxiety disorders in a national cohort of psychiatrically referred children and adolescents. , 2010, Journal of anxiety disorders.
[150] H. Rittmannsberger. The use of drug monotherapy in psychiatric inpatient treatment , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[151] C. Ernest,et al. Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics , 2002, Journal of clinical pharmacology.
[152] J. Calabrese,et al. A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. , 2008, Journal of child and adolescent psychopharmacology.
[153] J. Rushton,et al. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. , 2001, Archives of pediatrics & adolescent medicine.
[154] M. Keshavan,et al. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. , 1998, Journal of child and adolescent psychopharmacology.
[155] J. Swanson,et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.